thalidomide has been researched along with Complication, Postoperative in 15 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has been known to have immunosuppressive properties for over 20 years, but it has only recently been used in GVHD." | 6.38 | Thalidomide in the treatment of graft-versus-host disease. ( Bailey, CC; Heney, D; Lewis, IJ, 1990) |
| " The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT." | 4.93 | Venous thromboembolism in hematopoietic stem cell transplant recipients. ( Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U, 2016) |
| "Thalidomide has been known to have immunosuppressive properties for over 20 years, but it has only recently been used in GVHD." | 2.38 | Thalidomide in the treatment of graft-versus-host disease. ( Bailey, CC; Heney, D; Lewis, IJ, 1990) |
| "Thalidomide was started at the dose of 1." | 1.62 | Thalidomide as treatment of crohn-like disease occurred after allogeneic hematopoietic stem cell transplantation in a pediatric patient. ( Arrigo, S; Bava, C; Coccia, C; Faraci, M; Gandullia, P; Giardino, S; Pierri, F, 2021) |
| "De novo Crohn's disease (CD) is an increasingly reported diagnosis after ileal pouch anal anastomosis (IPAA)." | 1.56 | Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. ( Caime, F; Dipasquale, V; Romano, C; Tropeano, A, 2020) |
| "Thalidomide is an anti-angiogenic compound that may offer a potential option for management of refractory LVAD-related GIB." | 1.46 | Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients. ( Chan, LL; Kerk, KL; Lim, CP; Seng, BJJ; Sim, DKL; Sivathasan, C; Soon, JL; Tan, TE; Teo, LLY, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Heo, Y | 1 |
| Park, HS | 1 |
| Shin, CS | 1 |
| Yoo, KC | 1 |
| Kim, D | 1 |
| Lee, T | 1 |
| Dipasquale, V | 1 |
| Tropeano, A | 1 |
| Caime, F | 1 |
| Romano, C | 1 |
| Giardino, S | 1 |
| Bava, C | 1 |
| Arrigo, S | 1 |
| Pierri, F | 1 |
| Gandullia, P | 1 |
| Coccia, C | 1 |
| Faraci, M | 1 |
| Seng, BJJ | 1 |
| Teo, LLY | 1 |
| Chan, LL | 1 |
| Sim, DKL | 1 |
| Kerk, KL | 1 |
| Soon, JL | 1 |
| Tan, TE | 1 |
| Sivathasan, C | 1 |
| Lim, CP | 1 |
| Mesa-Gutiérrez, JC | 1 |
| Rouras-López, A | 1 |
| Amías-Lamana, V | 1 |
| Hoyos-Chacón, J | 1 |
| Cabiró-Badimón, I | 1 |
| Porta-Monnet, J | 1 |
| Chaturvedi, S | 1 |
| Neff, A | 1 |
| Nagler, A | 1 |
| Savani, U | 1 |
| Mohty, M | 1 |
| Savani, BN | 1 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Mall, JW | 1 |
| Schwenk, W | 1 |
| Philipp, AW | 1 |
| Müller, JM | 1 |
| Pollmann, C | 1 |
| SURUGA, K | 1 |
| Zangari, M | 1 |
| Elice, F | 1 |
| Fink, L | 1 |
| Tricot, G | 1 |
| Uthoff, K | 1 |
| Zehr, KJ | 1 |
| Gaudin, PB | 1 |
| Kumar, P | 1 |
| Cho, PW | 1 |
| Vogelsang, G | 1 |
| Hruban, RH | 1 |
| Baumgartner, WA | 1 |
| Stuart, RS | 1 |
| Schuler, U | 1 |
| Ehninger, G | 1 |
| Urata, K | 1 |
| Brault, A | 1 |
| Rocheleau, B | 1 |
| Huet, PM | 1 |
| Heney, D | 1 |
| Bailey, CC | 1 |
| Lewis, IJ | 1 |
| Schärli, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study of Thrombosis / Bleeding Incidence and Prophylaxis Trends[NCT05396157] | 813 participants (Actual) | Observational | 2021-11-01 | Active, not recruiting | |||
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus[NCT00001680] | Phase 2 | 17 participants | Interventional | 1997-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for thalidomide and Complication, Postoperative
| Article | Year |
|---|---|
Venous thromboembolism in hematopoietic stem cell transplant recipients.
Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Mu | 2016 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Thrombosis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines | 2007 |
Thalidomide: rationale for renewed use in immunological disorders.
Topics: Bone Marrow Transplantation; Cell Adhesion Molecules; Female; HIV Infections; Humans; Immune System | 1995 |
Thalidomide in the treatment of graft-versus-host disease.
Topics: Bone Marrow Transplantation; Child, Preschool; Graft vs Host Disease; Humans; Male; Postoperative Co | 1990 |
10 other studies available for thalidomide and Complication, Postoperative
| Article | Year |
|---|---|
Successful Treatment of Life-Threatening Small Bowel Bleeding With Thalidomide After Living Donor Kidney Transplantation: A Case Report.
Topics: Aged; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Kidney | 2019 |
Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.
Topics: Child, Preschool; Colitis, Ulcerative; Crohn Disease; Humans; Male; Postoperative Complications; Pro | 2020 |
Thalidomide as treatment of crohn-like disease occurred after allogeneic hematopoietic stem cell transplantation in a pediatric patient.
Topics: Child; Child, Preschool; Crohn Disease; Female; Hematopoietic Stem Cell Transplantation; Humans; Imm | 2021 |
Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart-Assi | 2017 |
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corn | 2013 |
Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits.
Topics: Angiogenesis Inhibitors; Animals; Colon; Female; Injections, Intraperitoneal; Postoperative Complica | 2002 |
[THALIDOMIDE ABNORMALITIES].
Topics: Abnormalities, Drug-Induced; Child; Child Care; Child Welfare; Ectromelia; Humans; Infant, Newborn; | 1964 |
Thalidomide as replacement for steroids in immunosuppression after lung transplantation.
Topics: Animals; Azathioprine; Cyclosporine; Dogs; Graft Rejection; Immunosuppressive Agents; Lung; Lung Tra | 1995 |
Role of Kupffer cells in the survival after rat liver transplantation with long portal vein clamping times.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Allopurinol; Animals; Calcium Channel Blockers; Cell C | 2000 |
[Congenital abnormalities of rectum and anus. Diagnosis, physiology and therapy].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anal Canal; Anus, Imperforate; Congenital Abno | 1971 |